Analyst Ratings for Harmony Biosciences
Portfolio Pulse from Benzinga Insights
Analysts have provided ratings for Harmony Biosciences (NASDAQ:HRMY) within the last quarter. The company received 10 bullish, 3 somewhat bullish, and 2 bearish ratings. The average price target is $54.2, compared to the current price of $21.9562, implying an upside. The average has decreased by 0.17% from the previous average price target of $54.29.
October 16, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Harmony Biosciences received mostly bullish ratings from analysts, implying a potential upside.
The majority of the analysts have given Harmony Biosciences a bullish rating, indicating a positive outlook for the company. The average price target is significantly higher than the current price, suggesting a potential upside. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100